bacopaside i

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bacopaside I: isolated from Bacopa monniera Wettst; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Bacopa	genus	A plant genus of the family Plantaginaceae. Members contain bacopaside, bacopasaponins and other dammarane type jujubogenins.[MeSH]	Plantaginaceae	A plant family of order Lamiales. The Plantago genus is best known. Lesser known members include Hippuris, Littorella and Callitriche.[MeSH]

Cross-References

ID Source	ID
PubMed CID	21599442
MeSH ID	M0408600

Synonyms (14)

Synonym
bacopaside i
3-o-alpha-l-arabinofuranosyl-(1-2)-(6-o-sulphonyl-beta-d-glucopyranosyl-(1-3))-alpha-l-arabinopyranosyl pseudo-jujubogenin
382148-47-2
unii-36b8wua361
36B8WUA361 ,
bacopaside i, (-)-
bacopaside i (constituent of bacopa) [dsc]
[(2r,3s,4s,5r,6s)-6-[(2s,3r,4s,5s)-3-[(2s,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5-hydroxy-2-[[(1s,2r,5r,7s,10r,11r,14r,15s,16s,17r,20r)-16-hydroxy-2,6,6,10,16-pentamethyl-17-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.
bacopaside i(sh)
HY-N4246
CS-0032525
Q27256548
AS-82791
AKOS040760286

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" This method was successfully applied to the preclinical pharmacokinetic study of bacopaside I following intravenous or oral administration to rats."	( A simple LC-ESI-MS/MS method for quantification of bacopaside I in rat plasma and its application to a pharmacokinetic study. Song, ZM; Wen, SM; Xiong, K; Xu, F; Yin, RF, 2016)	0.91

Bioavailability

Excerpt	Reference	Relevance
" Bioavailability as well as binding of neuroprotective agents (such as bacosides) to these receptors is controlled by the Blood Brain Barrier (BBB)."	( Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I. Baby, S; Sekhar, VC; Viswanathan, G, 2019)	0.75

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (19.05)	29.6817
2010's	15 (71.43)	24.3611
2020's	2 (9.52)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	21.21 (24.57)
Research Supply Index	3.18 (2.92)
Research Growth Index	5.09 (4.65)
Search Engine Demand Index	18.60 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (21.21)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (13.04%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (86.96%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.08	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.49	2	dialdehyde	biomarker
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	2.31	1	organic cation	geroprotector; herbicide
cadmium Cadmium: An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.. elemental cadmium : An element in the zinc group of the periodic table with atomic number 48, atomic mass 112, M.P. 321degreeC, and B.P. 765degreeC). An odourless, tasteless, and highly poisonous soft, ductile, lustrous metal with electropositive properties. It has eight stable isotopes: (106)Cd, (108)Cd,(110)Cd, (111)Cd, (112)Cd, (113)Cd, (114)Cd and (116)Cd, with (112)Cd and (114)Cd being the most common.	7.1	1	cadmium molecular entity; zinc group element atom
glycosides [no description available]	4.05	4
trimethyltin trimethyltin : An organotin compound that consists of stannane in which three of the four hydrogens are substituted by methyl groups.	2.25	1
beta-escin [no description available]	6.44	21
bacopaside ii bacopaside II: isolated from Bacopa monniera Wettst; structure in first source	4.24	5
jujubogenin jujubogenin: dammarane type triterpene	2.02	1
bacopasaponin c bacopasaponin C: triterpene glycoside from Indian medicinal plant Bacopa monniera (b. brahmi); a glycosidic pseudojujobogenin with glucose and rhamnose at the 3-position;	3.83	3
bacoside a3 bacoside A3: from Bacopa monniera; structure given in first source	4.14	2	triterpenoid
bacoside a bacoside A: from Bacopa monnieri; structure in first source	4.61	4	triterpenoid saponin
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.13	1	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite

Condition	Relationship Strength	Studies
Age-Related Memory Disorders [description not available]	2.25	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.25	1
Chronic Illness [description not available]	2.15	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.15	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	2.15	1
Ptosis, Eyelid [description not available]	2.08	1
Hypothermia, Accidental [description not available]	2.08	1
Blepharoptosis Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.	2.08	1
Hypothermia Lower than normal body temperature, especially in warm-blooded animals.	2.08	1
Acute Onset Vascular Dementia [description not available]	2.11	1
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	7.11	1
Dementia, Vascular An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)	2.11	1
Acute Confusional Senile Dementia [description not available]	2.13	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.13	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.13	1
Cerebral Ischemia [description not available]	2.08	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.08	1
Pain, Chronic [description not available]	3	1
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	3	1

chemdatabank.com